Spitz tumor with RAF1 fusion: A report of 3 cases.


Journal

Annals of diagnostic pathology
ISSN: 1532-8198
Titre abrégé: Ann Diagn Pathol
Pays: United States
ID NLM: 9800503

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 21 08 2023
revised: 03 10 2023
accepted: 04 10 2023
medline: 29 11 2023
pubmed: 20 10 2023
entrez: 19 10 2023
Statut: ppublish

Résumé

Spitz tumors are melanocytic neoplasms morphologically characterized by spindled and/or epithelioid cells and specific stromal and epidermal changes associated with mutually exclusive fusion kinases involving ALK, ROS1, NTRK1, NTRK2, NTRK3, MET and RET, BRAF and MAP3K8 genes or, less commonly, HRAS mutation. RAF1 fusions have been recently detected in cutaneous melanocytic neoplasms, including conventional melanoma, congenital nevus and BAP-1 inactivated tumors. We report herewith three Spitz neoplasms with a RAF1 fusion, including a previously reported CTDSPL::RAF1 fusion and two novel PPAP2B::RAF1 and ATP2B4::RAF1 fusions. Two cases were classified as Spitz nevus, while the remaining neoplasm was classified as Spitz melanoma at the time of the diagnosis, given 9p21 homozygous deletion and positive sentinel lymph node biopsy. We suggest that RAF1 fused melanocytic neoplasms can represent a novel subgroup of Spitz tumors, with a RAF1 fusion representing an oncogenic driver.

Identifiants

pubmed: 37856952
pii: S1092-9134(23)00113-2
doi: 10.1016/j.anndiagpath.2023.152215
pii:
doi:

Substances chimiques

Protein-Tyrosine Kinases EC 2.7.10.1
Proto-Oncogene Proteins 0
Receptor Protein-Tyrosine Kinases EC 2.7.10.1

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

152215

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Dr. Gerami has served as a consultant for DermTech Inc. and Castle Biosciences and has received royalties for textbooks from Elsevier. All other authors report no conflicts of interest.

Auteurs

Michele Donati (M)

Department of Pathology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy. Electronic address: micheledonati25@gmail.com.

Daniel Nosek (D)

Department of Pathology, Umeå University, Umeå, Sweden.

Shantel Olivares (S)

Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Julie Lemahieu (J)

Dermpat Laboratory, Ghent, Belgium.

Siebe Loontiens (S)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium; Molecular Diagnostics Ghent University Hospital (MDG), Ghent, Belgium; CRIG, Cancer Research Institute Ghent, Ghent University Hospital, Ghent, Belgium.

Boulos Mansour (B)

Department of Pathology, Ospedale Israelitico di Roma, Rome, Italy.

Pedram Gerami (P)

Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Dmitry V Kazakov (DV)

IDP Institut für Dermatohistopathologie, Pathologie Institut Enge, Zürich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH